Literature DB >> 25574106

Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations.

Dilek Cevik1, Gokhan Yildiz1, Mehmet Ozturk1.   

Abstract

AIM: To determine the mutation status of human telomerase reverse transcriptase gene (TERT) promoter region in hepatocellular carcinoma (HCC) from different geographical regions.
METHODS: We analyzed the genomic DNA sequences of 59 HCC samples comprising 15 cell lines and 44 primary tumors, collected from patients living in Asia, Europe and Africa. We amplified a 474 bp DNA fragment of the promoter region of TERT gene including the 1295228 and 1295250 sequence of chromosome 5 by using PCR. Amplicons were then sequenced by Sanger technique and the sequence data were analyzed with by using DNADynamo software in comparison with wild type TERT gene sequence as a reference.
RESULTS: The TERT mutations were found highly frequent in HCC. Eight of the fifteen tested cell lines displayed C228T mutation, and one had C250T mutation with a mutation frequency up to 60%. All of the mutations were heterozygous and mutually exclusive. Ten out of forty-four tumors displayed C228T mutation, and additional five tumors had C250T mutation providing evidence for mutation frequency of 34% in primary tumors. Considering the geographic origins of HCC tumors tested, TERT promoter mutation frequencies were higher in African (53%), when compared to non-African (24%) tumors (P = 0.056). There was also a weak inverse correlation between TERT promoter mutations and murine double minute 2 single nucleotide polymorphism 309 TG polymorphism (P = 0.058). Mutation frequency was nearly two times higher in established HCC cell lines (60%) compared to the primary tumors (34%).
CONCLUSION: TERT promoter is one of most frequent mutational targets in liver cancer, and hepatocellular carcinogenesis is highly associated with the loss of telomere-dependent cellular senescence control.

Entities:  

Keywords:  Cellular immortality; Hepatocellular carcinoma; Liver cancer; Promoter mutation; Telomerase reverse transcriptase; Telomerase reverse transcriptase gene

Mesh:

Substances:

Year:  2015        PMID: 25574106      PMCID: PMC4284350          DOI: 10.3748/wjg.v21.i1.311

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  31 in total

1.  Molecular biology. Wnt regulates TERT--putting the horse before the cart.

Authors:  Carol W Greider
Journal:  Science       Date:  2012-06-22       Impact factor: 47.728

2.  Highly prevalent TERT promoter mutations in bladder cancer and glioblastoma.

Authors:  Xiaoli Liu; Guojun Wu; Yuan Shan; Christian Hartmann; Andreas von Deimling; Mingzhao Xing
Journal:  Cell Cycle       Date:  2013-04-19       Impact factor: 4.534

Review 3.  Alternative lengthening of telomeres: models, mechanisms and implications.

Authors:  Anthony J Cesare; Roger R Reddel
Journal:  Nat Rev Genet       Date:  2010-03-30       Impact factor: 53.242

4.  Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease.

Authors:  Iñigo Landa; Ian Ganly; Timothy A Chan; Norisato Mitsutake; Michiko Matsuse; Tihana Ibrahimpasic; Ronald A Ghossein; James A Fagin
Journal:  J Clin Endocrinol Metab       Date:  2013-07-05       Impact factor: 5.958

Review 5.  Treatment of hepatocellular carcinoma: a systematic review.

Authors:  Shibo Lin; Katrin Hoffmann; Peter Schemmer
Journal:  Liver Cancer       Date:  2012-11       Impact factor: 11.740

6.  Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma.

Authors:  Wing-Kin Sung; Hancheng Zheng; Shuyu Li; Ronghua Chen; Xiao Liu; Yingrui Li; Nikki P Lee; Wah H Lee; Pramila N Ariyaratne; Chandana Tennakoon; Fabianus H Mulawadi; Kwong F Wong; Angela M Liu; Ronnie T Poon; Sheung Tat Fan; Kwong L Chan; Zhuolin Gong; Yujie Hu; Zhao Lin; Guan Wang; Qinghui Zhang; Thomas D Barber; Wen-Chi Chou; Amit Aggarwal; Ke Hao; Wei Zhou; Chunsheng Zhang; James Hardwick; Carolyn Buser; Jiangchun Xu; Zhengyan Kan; Hongyue Dai; Mao Mao; Christoph Reinhard; Jun Wang; John M Luk
Journal:  Nat Genet       Date:  2012-05-27       Impact factor: 38.330

Review 7.  Senescence and immortality in hepatocellular carcinoma.

Authors:  Mehmet Ozturk; Ayca Arslan-Ergul; Sevgi Bagislar; Serif Senturk; Haluk Yuzugullu
Journal:  Cancer Lett       Date:  2008-12-12       Impact factor: 8.679

Review 8.  Telomerase at the intersection of cancer and aging.

Authors:  Bruno Bernardes de Jesus; Maria A Blasco
Journal:  Trends Genet       Date:  2013-07-19       Impact factor: 11.639

Review 9.  Genetics and epigenetics of liver cancer.

Authors:  Cigdem Ozen; Gokhan Yildiz; Alper Tunga Dagcan; Dilek Cevik; Aysegul Ors; Umur Keles; Hande Topel; Mehmet Ozturk
Journal:  N Biotechnol       Date:  2013-02-04       Impact factor: 5.079

10.  Genome-wide transcriptional reorganization associated with senescence-to-immortality switch during human hepatocellular carcinogenesis.

Authors:  Gokhan Yildiz; Ayca Arslan-Ergul; Sevgi Bagislar; Ozlen Konu; Haluk Yuzugullu; Ozge Gursoy-Yuzugullu; Nuri Ozturk; Cigdem Ozen; Hilal Ozdag; Esra Erdal; Sedat Karademir; Ozgul Sagol; Dilsa Mizrak; Hakan Bozkaya; Hakki Gokhan Ilk; Ozlem Ilk; Biter Bilen; Rengul Cetin-Atalay; Nejat Akar; Mehmet Ozturk
Journal:  PLoS One       Date:  2013-05-15       Impact factor: 3.240

View more
  29 in total

Review 1.  Molecular Pathogenesis of Liver Cancer.

Authors:  Mehmet Ozturk; Tugce Batur; Umut Ekin; Aybike Erdogan; Evin İscan; Umur Keles; Ozden Oz; Cigdem Ozen
Journal:  J Gastrointest Cancer       Date:  2017-09

Review 2.  Virus-induced hepatocellular carcinoma with special emphasis on HBV.

Authors:  Ming Wang; Dong Xi; Qin Ning
Journal:  Hepatol Int       Date:  2017-01-17       Impact factor: 6.047

3.  GTSF1 gene may serve as a novel potential diagnostic biomarker for liver cancer.

Authors:  De-Yong Gao; Yun Ling; Xiao-Li Lou; Ying-Ying Wang; Liang-Ming Liu
Journal:  Oncol Lett       Date:  2017-12-27       Impact factor: 2.967

4.  TERT Genetic Mutations as Prognostic Marker in Glioma.

Authors:  Peiliang Geng; Xiaoxin Zhao; Juanjuan Ou; Jianjun Li; Rina Sa; Houjie Liang
Journal:  Mol Neurobiol       Date:  2016-05-20       Impact factor: 5.590

Review 5.  Understanding TERT Promoter Mutations: A Common Path to Immortality.

Authors:  Robert J A Bell; H Tomas Rube; Ana Xavier-Magalhães; Bruno M Costa; Andrew Mancini; Jun S Song; Joseph F Costello
Journal:  Mol Cancer Res       Date:  2016-03-03       Impact factor: 5.852

Review 6.  The role of telomeres and telomerase in cirrhosis and liver cancer.

Authors:  Jean-Charles Nault; Massih Ningarhari; Sandra Rebouissou; Jessica Zucman-Rossi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-06-28       Impact factor: 46.802

Review 7.  Roles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapies.

Authors:  Mohammad A Jafri; Shakeel A Ansari; Mohammed H Alqahtani; Jerry W Shay
Journal:  Genome Med       Date:  2016-06-20       Impact factor: 11.117

Review 8.  Cancer-Specific Telomerase Reverse Transcriptase (TERT) Promoter Mutations: Biological and Clinical Implications.

Authors:  Tiantian Liu; Xiaotian Yuan; Dawei Xu
Journal:  Genes (Basel)       Date:  2016-07-18       Impact factor: 4.096

Review 9.  Telomeres, NAFLD and Chronic Liver Disease.

Authors:  Benedetta Donati; Luca Valenti
Journal:  Int J Mol Sci       Date:  2016-03-15       Impact factor: 5.923

Review 10.  Transcription Regulation of the Human Telomerase Reverse Transcriptase (hTERT) Gene.

Authors:  Muhammad Khairul Ramlee; Jing Wang; Wei Xun Toh; Shang Li
Journal:  Genes (Basel)       Date:  2016-08-18       Impact factor: 4.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.